Skip to content

Replimune Group REPL Accrued expenses and other liabilities

Accrued expenses and other liabilities at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$2.72B+21.5%
Immunome logo
ImmunomeIMNM
CG Oncology logo
CG OncologyCGON
Erasca, Inc. logo
Erasca, Inc.ERAS

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+28.6%
Enterprise value$885.15M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's accrued expenses and other liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's accrued expenses and other liabilities?
Replimune Group (REPL) reported accrued expenses and other liabilities of $40.37M in Q4 2025.
How has Replimune Group's accrued expenses and other liabilities changed year-over-year?
Replimune Group's accrued expenses and other liabilities increased by 9.8% year-over-year, from $36.76M to $40.37M.
What is the long-term trend for Replimune Group's accrued expenses and other liabilities?
Over 4 years (2021 to 2025), Replimune Group's accrued expenses and other liabilities has grown at a 51.4% compound annual growth rate (CAGR), from $8.74M to $45.92M.